St. Jude Up 3% As Fitch Affirms Ratings, FDA Sets Date (for CardioMEMS)

By Dimitra DeFotis

Medical device maker St. Jude got a lift Friday for two reasons: Fitch Ratings maintained the company’s debt ratings and the FDA set an October 9 date for a review that could result in approval of a new heart device.

Shares of St. Jude Medical (STJ), best known for its implantable heart defibrillators, were up $1.70, or more than 3.%, to $52.66.

Fitch reiterated its bond ratings…